Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$69.39 ▲ +3.19
(+4.82%)
MKT CAP: $16.40B • VOL: 5.07M
52W L $36 52W H $72
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$58
MEDIAN
$78
MEAN
$79
HIGH
$94
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE EXEL TAPE
EXEL // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $83.96 | $79.80 | 2025-02-14 | $63.14 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $87.43 | $81.88 | 2025-02-06 | $65.23 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $79.10 | $76.33 | 2025-01-29 | $66.61 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $70.78 | — | 2025-01-17 | $68.00 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $61.06 | $65.92 | 2025-01-09 | $61.76 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $82.57 | $72.17 | 2024-12-18 | $60.37 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $67.31 | $70.08 | 2024-12-04 | $64.53 | -4.3% | 48% | C |